GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » Change In Payables And Accrued Expense

Chong Kun Dang Pharmaceutical (XKRX:185750) Change In Payables And Accrued Expense : ₩0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical Change In Payables And Accrued Expense?

Chong Kun Dang Pharmaceutical's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was ₩0 Mil. It means Chong Kun Dang Pharmaceutical's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Mar. 2024 .

Chong Kun Dang Pharmaceutical's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was ₩0 Mil. It means Chong Kun Dang Pharmaceutical's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .


Chong Kun Dang Pharmaceutical Change In Payables And Accrued Expense Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical Change In Payables And Accrued Expense Chart

Chong Kun Dang Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Chong Kun Dang Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Chong Kun Dang Pharmaceutical Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chong Kun Dang Pharmaceutical Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Chong Kun Dang Pharmaceutical (XKRX:185750) Business Description

Traded in Other Exchanges
N/A
Address
368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical (XKRX:185750) Headlines

No Headlines